In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 2213-63-0, name is 2,3-Dichloroquinoxaline, introducing its new discovery. Recommanded Product: 2,3-Dichloroquinoxaline
Indole derivatives for providing analgesic and anti-inflammatory effects
1-(Heterocyclic)-indol-3-ylacetic acid derivatives, processes for their preparation, and pharmaceutical compositions comprising them. An illustrative compound of the invention is 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid. The compounds have anti-inflammatory, analgesic and antipyretic activity. This application is a continuation-in-part of Ser. No. 296,202, filed Oct. 10, 1972, now U.S. Pat. No. 3,884,919.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 2213-63-0, and how the biochemistry of the body works.Recommanded Product: 2,3-Dichloroquinoxaline
Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1168 | ChemSpider